Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 배상철 | - |
dc.date.accessioned | 2017-03-31T06:28:11Z | - |
dc.date.available | 2017-03-31T06:28:11Z | - |
dc.date.issued | 2015-07 | - |
dc.identifier.citation | ARTHRITIS & RHEUMATOLOGY, v. 67, NO 7, Page. 1837-1847 | en_US |
dc.identifier.issn | 2326-5191 | - |
dc.identifier.issn | 2326-5205 | - |
dc.identifier.uri | http://onlinelibrary.wiley.com/doi/10.1002/art.39111/full | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/26494 | - |
dc.description.abstract | ObjectiveTo examine the frequency, characteristics, and outcome of mood disorders, as well as clinical and autoantibody associations, in a multiethnic/racial, prospective inception cohort of patients with systemic lupus erythematosus (SLE). MethodsPatients were assessed annually for mood disorders (4 types, according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) and 18 other neuropsychiatric events. Global disease activity scores (SLE Disease Activity Index 2000 [SLEDAI-2K]), damage scores (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index [SDI]), and Short Form 36 subscales, mental and physical component summary scores were collected. Time to event, linear and ordinal regressions, and multi-state models were used as appropriate. ResultsAmong the 1,827 patients with SLE, 88.9% were female, and 48.9% were Caucasian. The mean SD age of the patients was 35.1 +/- 13.3 years, disease duration was 5.6 +/- 4.8 months, and the length of followup was 4.7 +/- 3.5 years. During the course of the study, 863 (47.2%) of the 1,827 patients had 1,627 neuropsychiatric events. Mood disorders occurred in 232 (12.7%) of 1,827 patients, and 98 (38.3%) of 256 mood disorder events were attributed to SLE. The estimated cumulative incidence of any mood disorder after 10 years was 17.7% (95% confidence interval 15.1, 20.2%). A greater risk of mood disorder was associated with concurrent neuropsychiatric events (P0.01), and a lower risk was associated with Asian race/ethnicity (P=0.01) and treatment with immunosuppressive drugs (P=0.003). Mood disorders were associated with lower mental health and mental component summary scores but not with the SLEDAI-2K, SDI, or lupus autoantibodies. Among the 232 patients with depression, 168 (72.4%) were treated with antidepressants. One hundred twenty-six (49.2%) of 256 mood disorders resolved in 117 (50.4%) of 232 patients. ConclusionMood disorders, the second most frequent neuropsychiatric event in patients with SLE, have a negative impact on health-related quality of life and improve over time. The lack of association with global SLE disease activity, cumulative organ damage, and lupus autoantibodies emphasizes the multifactorial etiology of mood disorders and a role for non-lupus-specific therapies. | en_US |
dc.description.sponsorship | Dr. Hanly's work was supported by the Canadian Institutes of Health Research (grant MOP-86526). Drs. Su and Farewell's work was supported by the Medical Research Council, UK (grant U105261167). Dr. Gordon's work was supported by Lupus UK and the NIHR/Wellcome Trust Clinical Research Facility. Dr. Bae's work was supported by the Ministry for Health and Welfare, Republic of Korea (Korea Healthcare Technology R&D project A120404). Dr. Clarke holds The Arthritis Society Chair in Rheumatic Diseases at the University of Calgary. Dr. Bruce's work was supported by Arthritis Research UK, the NIHR (Biomedical Research Unit funding), the NIHR Manchester Biomedical Research Centre, and the NIHR/Wellcome Trust Clinical Research Facility at Central Manchester Foundation Trust. Dr. Dooley's work was supported by the NIH (grant RR-00046). Dr. Fortin's work was supported in part by a Distinguished Senior Investigator award from The Arthritis Society; he presently holds a Tier 1 Canada Research Chair on Systemic Autoimmune Rheumatic Diseases at Universite Laval. Dr. Ramsey-Goldman's work was supported by the NIH (grants 8-UL-1TR-000150 [formerly UL-1RR-025741], K24-AR-2318, and P60-AR-4464 [formerly P60-AR-8098]). Dr. Ruiz-Irastorza's work was supported by the Department of Education, Universities, and Research of the Basque Government. Dr. Jacobsen's work was supported by the Danish Rheumatism Association (grant A1028) and the Novo Nordisk Foundation (grant A05990). The Johns Hopkins Lupus Cohort is supported by the NIH (grant AR-43727). The Montreal General Hospital Lupus Clinic is supported in part by the Singer Family Fund for Lupus Research. Dr. Bruce has received consulting fees from Eli Lilly, GlaxoSmithKline, MedImmune, Merck Serono, UCB, and Roche (less than $10,000 each). Dr. Fortin has received consulting fees, speaking fees, and/or honoraria from Eli Lilly, AbbVie, and GlaskoSmithKline (less than $10,000 each). | en_US |
dc.language.iso | en | en_US |
dc.publisher | WILEY-BLACKWELL | en_US |
dc.subject | QUALITY-OF-LIFE | en_US |
dc.subject | NEUROPSYCHIATRIC EVENTS | en_US |
dc.subject | ANTIPHOSPHOLIPID ANTIBODIES | en_US |
dc.subject | COGNITIVE IMPAIRMENT | en_US |
dc.subject | PROTEIN-S | en_US |
dc.subject | PREVALENCE | en_US |
dc.subject | DEPRESSION | en_US |
dc.subject | SF-36 | en_US |
dc.subject | EPIDEMIOLOGY | en_US |
dc.subject | METAANALYSIS | en_US |
dc.title | Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study | en_US |
dc.type | Article | en_US |
dc.relation.no | 7 | - |
dc.relation.volume | 67 | - |
dc.identifier.doi | 10.1002/art.39111 | - |
dc.relation.page | 1837-1847 | - |
dc.relation.journal | ARTHRITIS & RHEUMATOLOGY | - |
dc.contributor.googleauthor | Hanly, John G. | - |
dc.contributor.googleauthor | Su, Li | - |
dc.contributor.googleauthor | Urowitz, Murray B. | - |
dc.contributor.googleauthor | Romero-Diaz, Juanita | - |
dc.contributor.googleauthor | Gordon, Caroline | - |
dc.contributor.googleauthor | Bae, Sang-Cheol | - |
dc.contributor.googleauthor | Bernatsky, Sasha | - |
dc.contributor.googleauthor | Clarke, Ann E. | - |
dc.contributor.googleauthor | Wallace, Daniel J. | - |
dc.contributor.googleauthor | Merrill, Joan T. | - |
dc.relation.code | 2015000228 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | scbae | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.